Skip to main content
Advertisement
  • Other Publications
    • EMBO Press
    • The EMBO Journal (Home)
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Life Science Alliance
Login

   

Search

Advanced Search

Journal

  • Home
  • Latest Online
  • Current Issue
  • Archive
  • Subject Collections
  • Review Series & Focuses

Authors & Referees

  • Submit
  • Author Guidelines
  • Aims & Scope
  • Editors & Board
  • Transparent Process
  • Bibliometrics
  • Referee Guidelines
  • Open Access Charges

Info

  • E-Mail Editorial Office
  • Alerts
  • RSS Feeds
  • Subscriptions & Access
  • Reprints & Permissions
  • Advertise & Sponsor
  • Media Partners
  • News & Press
  • Recommend to Librarian
  • Customer Service
  • Home
  • The EMBO Journal: 36 (6)

News & Views

Dangerous fusions: a path to cancer for arrested lymphoid progenitors

Ameera Alsadeq, Hassan Jumaa
DOI 10.15252/embj.201796686 | Published online 08.03.2017
The EMBO Journal (2017) 36, 705-706
Ameera Alsadeq
Institute of Immunology, Medical Center Ulm, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hassan Jumaa
Institute of Immunology, Medical Center Ulm, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Ameera Alsadeq1 and
  2. Hassan Jumaa (hassan.jumaa@uni-ulm.de)1
  1. 1 Institute of Immunology, Medical Center Ulm, Ulm, Germany
View Full Text
  • Article
  • Figures & Data
  • Transparent Process
Loading

B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a common malignancy associated with variable chromosomal translocations, leading to fusion proteins of unknown function. To investigate how such translocations contribute to the development of BCP‐ALL , Smeenk et al (2017) generated mouse models for Pax5 fusion proteins. The results show that a PAX5 fusion is required for BCP‐ALL development by preventing B‐cell differentiation and retaining cells in an arrested progenitor stage. The occurrence of further genetic aberrations eventually results in oncogenic transformation and proliferation of the arrested cells, triggering the onset of leukemia.

See also: L Smeenk et al (March 2017)

B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is the most common malignancy in children, and adults are also often diagnosed with this disease. Despite good prognosis in pediatric patient outcomes, at least 15% of patients suffer from relapse (Locatelli et al, 2012). Therefore, a deep understanding of the molecular mechanisms underlying the onset of this disease is needed to improve the current therapeutic approaches.

The commitment into the B‐cell lineage and the subsequent cell fate decisions are regulated through different checkpoints that involve a complex transcriptional regulation. The paired box domain gene 5 (PAX5) is one of the crucial transcription factors required for maintaining B‐cell identity and for further development. PAX5 is considered to be a haploinsufficient tumor suppressor in BCP‐ALL, as heterozygous deletions and loss‐of‐function mutations are detected in 30% of BCP‐ALL (Mullighan et al, 2007). Moreover, chromosomal translocations of PAX5 and various partners including JAK2, ETV6, FOXP1, ZNF521, KIDINS220, and ELN have been identified in about 2.5% of BCP‐ALL (Nebral et al, 2009). These BCP‐ALL cases often show genetic aberrations affecting one allele of PAX5 while retaining the second allele functional, most likely leading to reduced PAX5 expression. Since the affected allele is involved in chromosomal translocations leading to an abnormal fusion protein, an important question is whether this fusion product itself is involved in the initiation or maintenance of the disease.

Among the interesting chimeric fusions are PAX5‐ETV6 and PAX5‐FOXP1, which comprise not only the DNA‐binding paired box domain of PAX5 but also almost the entire coding sequence of ETV6 or FOXP1 transcription factors, as well as an oligomerization motif (Cazzaniga et al, 2001; Coyaud et al, 2010). So far, these fusions have mainly been examined using in vitro systems relying on transient overexpression in cell lines. These studies suggested that a dominant‐negative function of the fusion proteins interfered with wild‐type PAX5, thereby affecting survival pathways (Kawamata et al, 2012). However, the function of these fusion proteins in the pathogenesis of ALL in vivo remained unclear.

The generation of animal models for Pax5 mutations may help understand their function during differentiation of B‐cell progenitors and in the development of ALL. In fact, these models revealed that complete loss of Pax5 results in an early block of B‐cell differentiation, while conditional Pax5 deficiency induced dedifferentiation of mature B cells into uncommitted progenitors and was associated with aggressive tumors (Cobaleda et al, 2007). Moreover, haploinsufficiency of Pax5 was shown to synergize with the activation of signal transducer and activator of transcription 5 (Stat5) in promoting ALL development (Heltemes‐Harris et al, 2011). Now, the work of Smeenk et al (2017) provides novel knock‐in mouse models for two Pax5 fusions, namely Pax5‐Etv6 and Pax5‐Foxp1. This is the first study to describe the mode of action of the resulting fusion proteins in B‐cell development and to highlight the additional factors that promote the leukemogenesis in vivo.

Interestingly, neither heterozygous loss of Pax5 nor the individual expression of only the DNA‐binding paired box domain of Pax5 influenced B‐cell development. However, the heterozygous expression of the Pax5 fusion proteins Pax5‐Etv6 and Pax5‐Foxp1 led to a block in B‐cell development at the transition from the pro‐B to pre‐B‐cell stage, and a slight increase in the cell number of early B cells in comparison with control mice. This implies that the fusion proteins of Pax5 possess a distinct transcriptional activity that interferes with B‐cell development. However, the developmental blockage alone was not sufficient to drive BCP‐ALL, indicating that acquisition of synergistic cooperating mutations enhancing proliferation and/or survival is required for initiation or maintenance of malignant transformation. In human BCP‐ALL, the generation of PAX5‐ETV6 is known to co‐occur with the loss of one allele of the tumor suppressor CDKN2A/B locus (Strehl et al, 2003). In full agreement, the mouse model shows that the Pax5‐Etv6 fusion protein synergizes with the heterozygous loss of Cdkn2a/b in promoting BCP‐ALL, which was more aggressive under the complete loss of Cdkn2a/b. On the other hand, impairment of Cdkn2a/b expression did not lead to leukemia progression in Pax5‐Foxp1 knock‐in mice, suggesting that the secondary events driving malignancy in human BCP‐ALL are regulated differently in the case of PAX5‐FOXP1 fusion.

Altogether, the chromosomal alterations affecting Pax5 seem to act as first events for hematological malignancies by generating arrested lymphoid progenitors or “leukemia‐initiating cells”. These cells are kept in a “ready‐to‐go” state until acquiring secondary events (Fig 1), which may help “arrested cells” to proliferate and survive. Identification of these events is of great importance, as it allows a better understanding of malignant transformation and leukemogenesis. Crossing the knock‐in mice generated by Smeenk et al (2017) with mouse strains deficient for genes important for B‐cell differentiation or function could represent one approach to identify additional targets for secondary events. Moreover, introducing an experimental system for random mutagenesis into the knock‐in mice carrying Pax5 fusions may help identify novel mutations for BCP‐ALL development. For instance, transposon‐based insertional mutagenesis has been used to screen for novel secondary mutations (van der Weyden et al, 2011). Identifying novel mutations or commonly altered pathways during leukemic evolution is important not only for understanding the mechanism of malignant transformation but also for the development of novel therapeutic strategies.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1. Developmental arrest as the first step in leukemogenesis

During normal B‐cell generation, hematopoietic stem cells (HSC) give rise to progenitors that pass through steps of lineage commitment and differentiation to eventually become mature B cells. Chromosomal translocations that result in fusion proteins such as PAX5‐ETV6 block B‐cell differentiation and lead to a distinct population of early B cells with limited survival capacity under normal conditions. The occurrence of secondary mutations affecting tumor suppressors or oncogenes enhances proliferation or survival and initiates BCP‐ALL.

References

  1. ↵
    Cazzaniga G , Daniotti M , Tosi S , Giudici G , Aloisi A , Pogliani E , Kearney L , Biondi A (2001) The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res 61: 4666–4670
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Cobaleda C , Jochum W , Busslinger M (2007) Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449: 473–477
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Coyaud E , Struski S , Prade N , Familiades J , Eichner R , Quelen C , Bousquet M , Mugneret F , Talmant P , Pages MP , Lefebvre C , Penther D , Lippert E , Nadal N , Taviaux S , Poppe B , Luquet I , Baranger L , Eclache V , Radford I et al (2010) Wide diversity of PAX5 alterations in B‐ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood 115: 3089–3097
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Heltemes‐Harris LM , Willette MJ , Ramsey LB , Qiu YH , Neeley ES , Zhang N , Thomas DA , Koeuth T , Baechler EC , Kornblau SM , Farrar MA (2011) Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J Exp Med 208: 1135–1149
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kawamata N , Pennella MA , Woo JL , Berk AJ , Koeffler HP (2012) Dominant‐negative mechanism of leukemogenic PAX5 fusions. Oncogene 31: 966–977
    OpenUrlCrossRefPubMed
  6. ↵
    Locatelli F , Schrappe M , Bernardo ME , Rutella S (2012) How I treat relapsed childhood acute lymphoblastic leukemia. Blood 120: 2807–2816
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Mullighan CG , Goorha S , Radtke I , Miller CB , Coustan‐Smith E , Dalton JD , Girtman K , Mathew S , Ma J , Pounds SB , Su X , Pui CH , Relling MV , Evans WE , Shurtleff SA , Downing JR (2007) Genome‐wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758–764
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Nebral K , Denk D , Attarbaschi A , Konig M , Mann G , Haas OA , Strehl S (2009) Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23: 134–143
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Smeenk L , Fischer M , Jurado S , Jaritz M , Azaryan A , Werner B , Roth M , Zuber J , Stanulla M , den Boer ML , Mullighan CG , Strehl S , Busslinger M (2017) Molecular role of the PAX5‐ETV6 oncoprotein in promoting B‐cell acute lymphoblastic leukemia. EMBO J 36: 718–735
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Strehl S , Konig M , Dworzak MN , Kalwak K , Haas OA (2003) PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). Leukemia 17: 1121–1123
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    van der Weyden L , Giotopoulos G , Rust AG , Matheson LS , van Delft FW , Kong J , Corcoran AE , Greaves MF , Mullighan CG , Huntly BJ , Adams DJ (2011) Modeling the evolution of ETV6‐RUNX1‐induced B‐cell precursor acute lymphoblastic leukemia in mice. Blood 118: 1041–1051
    OpenUrlAbstract/FREE Full Text
  • © 2017 The Authors
View Abstract
Previous Article in this IssueNext Article in this Issue
Back to top

  • PDF
  • Share
  • Export
  • Print
Loading

PDF

In this Issue
Volume 36, Issue 6
15 March 2017 | pp 703 - 829
The EMBO Journal: 36 (6)
About the cover
Alert me when this article is cited
Alert me if a correction is posted

Article

  • Article
    • References
  • Figures & Data
  • Transparent Process

Related Content

More News & Views

  • Past stem cells and finally in transit: SLC1A3 instructs skin niche coupling
    Edwige Roy, Kiarash Khosrotehrani
    The EMBO Journal : e99393
  • Anti‐cancer therapy: senescence is the new black
    Rodrigo Leite de Oliveira, Rene Bernards
    The EMBO Journal : e99386
  • Pushed out of a tough crowd: centrosome aberrations promote invasiveness
    Lauren T Evans, Andrew J Holland
    The EMBO Journal : e99422
More News & Views

Related Articles

Cited By...

Request Permissions

Subject Areas

  • Cancer
  • Immunology
  • Transcription

Journal

  • Latest Online
  • Current Issue
  • Archive
  • Bibliometrics
  • E-Mail Editorial Office

Authors & Referees

  • Aims & Scope
  • Editors & Board
  • Transparent Process
  • Author Guidelines
  • Referee Guidelines
  • Open Access
  • Submit

Info

  • Alerts
  • RSS Feeds
  • Subscriptions & Access
  • Reprints & Permissions
  • Advertise & Sponsor
  • News & Press
  • Recommend to Librarian
  • Customer Service

EMBO

  • Funding & Awards
  • Events
  • Science Policy
  • Members
  • About EMBO

Online ISSN  1460-2075

Copyright© 2018 EMBO

This website is best viewed using the latest versions of all modern web browsers. Older browsers may not display correctly.